KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 4

The Value of Inflammatory Prognostic Index in Older Patients with Hormone Receptor Positive Metastatic Breast Cancer

Ahmet Dirican
Ferhat Ekinci
Esin Oktay
Bilgin Demir
Atike Pinar Erdogan
Ahmet Ozveren
Senem Yilmaz
Mustafa Sahin
Sayfa
515–520
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: To search the prognostic value of an inflammation based prognostic score in older patients with hormone positive, Her2 negative metastatic breast cancer.
📊
Temel Bulgular & Veri:Methods: A retrospective study of 82 female patients aged 65 years and older with hormon receptor positive, Her-2 negative metastatic breast cancer diagnosed between 2011 and 2018 was conducted with collection of clinical and laboratory data.
💡
Sonuç & Katkı:Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms
🔬Tür:Araştırma Makalesi
📍Kapsam:2011 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: To search the prognostic value of an inflammation based prognostic score in older patients with hormone positive, Her2 negative metastatic breast cancer. Methods: A retrospective study of 82 female patients aged 65 years and older with hormon receptor positive, Her-2 negative metastatic breast cancer diagnosed between 2011 and 2018 was conducted with collection of clinical and laboratory data. The inflammatory prognostic index (IPI) was calculated as C-reactive protein × NLR (neutrophil/ lym- phocyte ratio)/serum albumin. Survival estimates were calculated with Kaplan-Meier method. Results: The optimal cut-off points of IPI for the stratification of OS was found to be 0,75. Based on this cutoff value, patients were categorized as IPI-high and IPI-low group. High IPI was significantly associated with advanced stage at diagnosis. (p=0.03) The mean OS was 64 months in the IPI-high group and 66.9 months in the IPI-low group. (p=0,813) In patients receiving hormonotherapy in first line treatment PFS was 34.6 months in the IPI-low group and 14.5 months in the IPI high group, and a statistically significant difference was found compared to patients who received chemo- therapy in the first line. (p=0,042). Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms

🔖

Bu Makaleye Atıf Yap

Dirican, A., Ekinci, F., Oktay, E., Demir, B., Erdogan, A. P., Ozveren, A., Yilmaz, S., Sahin, M. (2022). The Value of Inflammatory Prognostic Index in Older Patients with Hormone Receptor Positive Metastatic Breast Cancer. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 4, 515–520. https://ajindex.com/articles/508548

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 1989;63:976–81
  2. Cancer Facts and Figures 2008. American Cancer Society, Surveillance Research. American Cancer Society, Atlanta, GA; 2008. Available from: https://www.cancer.org/research/ cancer-facts-statistics/all-cancer-facts-figures/cancer-facts- figures-2008.html 3. Jolly TA, Williams GR, Bushan S, Pergolotti M, Nyrop KA, Jones EL, et al. Adjuvant treatment for older women with invasive breast cancer. Womens Health (Lond) 2016;12:129–45
  3. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268–75
  4. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast can- cer patients aged 55 years and older. JAMA 2001;285:885–92
  5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next gen- eration. Cell 2011;144:646–74
  6. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary oper- able cancer. Future Oncol 2010;6:149–63
  7. Dirican N, Dirican A, Anar C, Atalay S, Ozturk O, Bircan A, et al. New inflammatory prognostic index, based on c-reactive pro- tein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer Cases. Asian Pac J Cancer Prev 2016;17:5101–6
  8. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–65. 10. van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, et al. Association between age at diag- nosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 2012;307:590–7
  9. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92;550–6
  10. MacDonald N. Cancer cachexia and targeting chronic inflam- mation: A unified approach to cancer treatment and pallia- tive/supportive care. J Support Oncol 2007;5:157–62
  11. Nishijima TF, Deal AM, Lund JL, Nyrop KA, Muss HB, Sanoff HK. Inflammatory markers and overall survival in older adults with cancer. J Geriatr Oncol 2019;10:279–84
  12. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J,